ONCOZ — Oncozenge AB Income Statement
0.000.00%
Last trade - 00:00- SEK70.82m
- SEK74.61m
- SEK2.66m
Annual income statement for Oncozenge AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PRESS | ARS | ARS | ARS | PRESS |
| Standards: | — | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 2.66 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4.89 | 43.6 | 15.9 | 8.69 | 18.5 |
| Operating Profit | -4.89 | -43.6 | -15.9 | -8.69 | -15.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -4.89 | -43.6 | -15.9 | -8.69 | -15.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.89 | -46.6 | -15.9 | -8.69 | -15.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.89 | -46.6 | -15.9 | -8.69 | -15.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.89 | -46.6 | -15.9 | -8.69 | -15.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.332 | -3.98 | -1.36 | -0.742 | -1.31 |
| Dividends per Share |